Cresset Asset Management’s ImmunityBio IBRX Stock Holding History

Cresset Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$440K	Sell	50,236 -63	-0.1%	-$477	﹤0.01%	1219
2026 Q1	$386K	Buy	50,299 +299	+0.6%	+$2.05K	﹤0.01%	1173
2025 Q4	$99K	Hold	50,000	–	–	﹤0.01%	1576
2025 Q3	$123K	Hold	50,000	–	–	﹤0.01%	1480
2025 Q2	$132K	Buy	+50,000	New	+$134K	﹤0.01%	1343

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cresset Asset Management's IBRX Position: Q2 2026 in Review

Cresset Asset Management reduced its ImmunityBio (IBRX) stake by 0.13% in Q2 2026, selling an estimated $477 and leaving 50,236 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Cresset Asset Management first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Cresset Asset Management held 50,236 shares of ImmunityBio worth $440K as of Q2 2026.
Cresset Asset Management sold 63 ImmunityBio shares in Q2 2026, an estimated $477.
ImmunityBio made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1219 holding.
Cresset Asset Management first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.